Belite Bio (BLTE) reported a Q3 net loss Tuesday of $0.28 per diluted share, narrowing from a loss of $0.40 a year earlier.
Analysts surveyed by Capital IQ expected a loss of $0.29.
The company did not report any revenue for the quarter ended Sept. 30, as expected.
As of Sept. 30, the company had $109 million in cash, money market fund, time deposits and US treasury bills, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments